No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Chenguang Biotech Group (300138.SZ): Net income for the year 2024 is expected to decline by 76.03%-83.32%.
Gelonghui, January 21st丨Chenguang Biotech Group (300138.SZ) announced the performance forecast for 2024, with revenue expected to be 6.89 billion yuan to 7.09 billion yuan, an increase of 0.27% to 3.18% compared to the same period last year; Net income attributable to shareholders of the listed company is expected to be 80 million yuan to 115 million yuan, a decrease of 83.32% to 76.03% compared to the same period last year; Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be 20 million yuan to 55 million yuan, a decrease of 94.55% to 85.02% compared to the same period last year. In 2024, affected by the macro.
Chenguang Biotech: 2024 Annual Results Forecast
Chenguang Biotech Group (300138.SZ): The subsidiary has been recognized as a high-tech enterprise.
On December 26, Gelonghui reported that Chenguang Biotech Group (300138.SZ) announced that according to the notice released on December 26, 2024, by the Office of the National High-Tech Enterprise Recognition Management Leading Group, the wholly-owned subsidiary of Chenguang Biotech Group Co., Ltd. — Guiyang Chenguang Biotech Co., Ltd. has been included in the first batch of high-tech enterprises recognized and reported by Guizhou Province in 2024, passing the high-tech enterprise recognition with certificate number: GR202452000132; issued.
Chenguang Biotech Group (300138.SZ): Plans to change part of the use of raised funds.
Gelonghui, on December 26, announced that Chenguang Biotech Group (300138.SZ) disclosed that, according to the company's development plan, in order to improve the efficiency of fundraising, it intends to change the use of part of the funds raised from the public issuance of convertible Bonds. A portion of the raised funds amounting to 45 million yuan originally allocated for the "Integrated Natural Plant Extraction Project (Phase I)" will be redirected for the "Health Food Construction Project of Chenguang Biotech Group Handan Co., Ltd.".
chenguang biotech group (300138.SZ): Currently no fertilizer business
Glonghui reported on November 28 that chenguang biotech group (300138.SZ) stated on the investor interaction platform that the company currently has no business in fertilizers. The byproducts such as residue from the production processes of the company's lutein and stevia products can be used as raw materials for downstream fertilizer companies.
ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) Low P/E No Reason For Excitement
